Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices

References

• Townsley DM, Battiwalla M. The Bethesda handbook of clinical hematology. In: Rodgers GP, Young NS, editors. Fourth edition. ed. Philadelphia, PA: Wolters Kluwer; 2019.
   Google Scholar
• Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121–7125. doi:10.1182/blood-2011-02-337964
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries. J Clin Oncol. 2010;28(17):2847–2852. doi:10.1200/JCO.2009.25.2395
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45–52. doi:10.1182/blood-2008-01-134858
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15. doi:10.1016/j.blre.2018.09.001
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-420489
   PubMed Web of Science ®Google Scholar
• Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence. 2022;1(7):EVIDoa2200008. doi:10.1056/EVIDoa2200008
   PubMedGoogle Scholar
• Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Leukemia. 2016;30(11):2214–2220. doi:10.1038/leu.2016.138
   PubMed Web of Science ®Google Scholar
• Nazha A, Komrokji R, Meggendorfer M, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39(33):3737–3746. doi:10.1200/JCO.20.02810
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232. doi:10.1016/S1470-2045(09)70003-8
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803. doi:10.1002/cncr.21792
   PubMed Web of Science ®Google Scholar
• Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–3327. doi:10.1200/JCO.2011.35.8135
   PubMed Web of Science ®Google Scholar
• Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49(4):690–695. doi:10.1080/10428190701882146
   PubMed Web of Science ®Google Scholar
• Stein EM, Bonifacio G, Latremouille-Viau D, et al. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Leuk Lymphoma. 2021;62(6):1411–1421. doi:10.1080/10428194.2020.1869959
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Salimi T, Epstein RS. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials? Future Oncol. 2021;17(36):5163–5175. doi:10.2217/fon-2021-0936
   PubMed Web of Science ®Google Scholar
• Stein EM, Bonifacio G, Latremouille-Viau D, et al. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. J Med Econ. 2021;24(1):234–243. doi:10.1080/13696998.2021.1876714
   PubMed Web of Science ®Google Scholar
• Zipperer E, Tanha N, Strupp C, et al. The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica. 2014;99(3):e31-2–e32. doi:10.3324/haematol.2013.101055
   PubMed Web of Science ®Google Scholar
• Corman S, Joshi N, Wert T, et al. Under-use of hypomethylating agents in patients with higher-risk myelodysplastic syndrome in the United States: a large population-based analysis. Clin Lymphoma Myeloma Leuk. 2021;21(2):e206–e211. doi:10.1016/j.clml.2020.10.013
   PubMed Web of Science ®Google Scholar
• Pease DF, Ross JA, Poynter JN, et al. Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. Cancer Epidemiol. 2015;39(2):222–228. Aprdoi:10.1016/j.canep.2015.01.006
   PubMed Web of Science ®Google Scholar
• Griffiths EA. Oral hypomethylating agents: beyond convenience in MDS. Hematology Am Soc Hematol Educ Program. 2021; Dec 102021(1):439–447. doi:10.1182/hematology.2021000278
   PubMedGoogle Scholar
• Bewersdorf JP, Zeidan AM. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: what is on the horizon? Best Pract Res Clin Haematol. 2021; 34(1):101245. doi:10.1016/j.beha.2021.101245
   PubMed Web of Science ®Google Scholar
• Cabrero M, Jabbour E, Ravandi F, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015;39(5):520–524. doi:10.1016/j.leukres.2015.03.006
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Joshi N, Kale H, et al. Impact of hypomethylating agent use on hospital and emergency room visits, and predictors of early discontinuation in patients with higher-risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2022;22(9):670–679. doi:10.1016/j.clml.2022.04.016
   PubMed Web of Science ®Google Scholar
• Abel GA, Buckstein R. Integrating frailty, comorbidity, and quality of life in the management of myelodysplastic syndromes. Am Soc Clin Oncol Educ Book. 2016;35:e337-44–e344. doi:10.1200/EDBK_158639
   PubMedGoogle Scholar
• Buckstein R, Wells RA, Zhu N, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174(1):88–101. doi:10.1111/bjh.14033
   PubMed Web of Science ®Google Scholar
• Joshi N, Kale H, Corman S, et al. Direct medical costs associated with treatment nonpersistence in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: a large retrospective cohort analysis. Clin Lymphoma Myeloma Leuk. 2021;21(3):e248–e254. doi:10.1016/j.clml.2020.12.002
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Cheung MC, Mittmann N, et al. Real-world costs of azacitidine treatment in patients with higher-risk myelodysplastic syndromes/low blast-count acute myeloid leukemia. J Clin Oncol Oncol Pract. 2021;17(4):e517–e525. doi:10.1200/OP.20.00446
   PubMedGoogle Scholar
• Mozessohn L, Cheung MC, Mittmann N, et al. Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the “real-world”. Leuk Lymphoma. 2020;61(6):1445–1454. Jundoi:10.1080/10428194.2020.1723012
   PubMed Web of Science ®Google Scholar